Abstract:Recombinant adeno-associated virus (AAV) has emerged as one of the most promising systems for therapeutic gene delivery and has demonstrated clinical success in a wide range of genetic disorders. However, manufacturing of high-quality AAV in large amounts still remains a challenge. A significant difficulty for downstream processing is the need to remove empty capsids that are generated in all currently utilized expression systems and that represent product-related impurities that adversely affect safety and efficacy of AAV vectors. Empty and full capsids exhibit only subtle differences in surface charge and size, making chromatography-based separations highly challenging. Here, we present a rapid methodology for the systematic process development of the crucial AAV full/empty capsid separation on ion-exchange media based on high-throughput screening and mechanistic modeling. Two of the most commonly employed serotypes, AAV8 and AAV9, are used as case studies. First, high-throughput studies in filter-plate format are performed that allow the rapid and comprehensive study of binding and elution behavior of AAV on different resins, using different buffer systems, pH, salt conditions, and solution additives. Small amounts of separated empty and full AAV capsids are generated by iodixanol gradient centrifugation that allow studying the binding and elution behavior of the two vector species separately in miniaturized format. Process conditions that result in maximum differences in elution behavior between empty and full capsids are then transferred to benchtop chromatography systems that are used to generate calibration data for the estimation of steric mass-action isotherm and mass transport parameters for process simulation. The resulting column models are employed for in-silico process development that serves to enhance understanding of separation constraints and to identify optimized conditions for the removal of empty particles. Finally, optimized separation conditions are verified experimentally. The methodology presented in this work provides a systematic framework that affords mechanistic understanding of the crucial empty/full capsid separation and accelerates the development of a scalable AAV downstream process.

Drug Product Formulation and Fill/Finish Manufacturing Process Considerations for AAV-based Genomic Medicines

Characterization of AAV vectors: A review of analytical techniques and critical quality attributes

Current progress and limitations of AAV mediated delivery of protein therapeutic genes and the importance of developing quantitative pharmacokinetic/pharmacodynamic (PK/PD) models

ACUVRA: Anion-Exchange Chromatography UV-Ratio Analysis-A QC-Friendly Method for Monitoring Adeno-Associated Virus Empty Capsid Content To Support Process Development and GMP Release Testing

Membrane chromatography for AAV full capsid enrichment: Process development to scale up

Comprehensive characterization and quantification of adeno associated vectors by size exclusion chromatography and multi angle light scattering

Advanced biomanufacturing and evaluation of adeno-associated virus

Critical challenges and advances in recombinant adeno‐associated virus (rAAV) biomanufacturing

Analytical characterization of full, intermediate, and empty AAV capsids

Design space determination to optimize DNA complexation and full capsid formation in transient rAAV manufacturing

Microfluidic AAV Purity Characterization: New Insights into Serotype and Sample Treatment Variability

Detailed Protocol for the Novel and Scalable Viral Vector Upstream Process for AAV Gene Therapy Manufacturing.

Adeno-associated virus as a delivery vector for gene therapy of human diseases

AAV Engineering for Improving Tropism to the Central Nervous System

Encapsulation of AAVs into protein vault nanoparticles as a novel solution to gene therapy’s neutralizing antibody problem

Optimization strategies and advances in the research and development of AAV‐based gene therapy to deliver large transgenes

Rational downstream development for adeno-associated virus full/empty capsid separation – A streamlined methodology based on high-throughput screening and mechanistic modeling

A Multifaceted Approach to Optimizing AAV Delivery to the Brain for the Treatment of Neurodegenerative Diseases

Rapid Characterization of Adeno-Associated Virus (AAV) Capsid Proteins using Microchip ZipChip CE-MS

The state of technological advancement to address challenges in the manufacture of rAAV gene therapies

Development of a scalable and robust AEX method for enriched rAAV preparations in genome-containing VCs of serotypes 5, 6, 8, and 9